PLSE
PULSE BIOSCIENCES, INC.
Next earnings Aug 10, 2026 · consensus $-0.37 EPS, $544K rev
Last earnings -3.8% on 2026-05-04
$28.45
▲ +3.44%$28.45▲ +85.95%
over 1Y
L $12.66EODHDH $28.45
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.4%
1W+10.7%
1M+15.1%
3M+38.3%
YTD+112.5%
1Y+85.9%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Conservative balance sheet (liabilities/equity 0.17x); but unprofitable (net margin -20794.6%).
PULSE BIOSCIENCES, INC. shows $350K in FY2025 revenue, a -20794.6% net margin, and -90.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.42M | $700K | $0.00 | $0.00 | $350K |
| Gross profit | — | — | — | — | — |
| Operating income | -$63.0M | -$58.1M | -$43.6M | -$56.3M | -$76.9M |
| Net income | -$63.7M | -$58.5M | -$42.2M | -$53.6M | -$72.8M |
| Diluted EPS | -$2.28 | — | — | — | — |
| Net margin | -4489.4% | -8357.9% | — | — | -20794.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.85B
EV / EBITDA—
EV / Sales5295.9
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-3.8%
FCF yield-2.8%
Quality & risk
ROIC (est.)-75.4%
Free cash flow-$54.4M
Total debt—
Net cash$80.7M
Altman Z-Score75.01 safe
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+1.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-04-30). Worth a closer look.
Recent filings
all on EDGAR ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗8-KPeriod ending 2026-06-112026-06-12open ↗8-KPeriod ending 2026-06-102026-06-10open ↗4/APeriod ending 2026-05-112026-05-15open ↗10-QPeriod ending 2026-03-312026-05-14open ↗SCHEDULE 13D/AFiling2026-05-13open ↗4/APeriod ending 2026-05-112026-05-11open ↗4Period ending 2026-05-112026-05-11open ↗
Frequently asked
- Is PULSE BIOSCIENCES, INC. (PLSE) a buy?
- PLSE currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.17x); but unprofitable (net margin -20794.6%).
- What is PULSE BIOSCIENCES, INC.'s quality score?
- PLSE scores 31/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001625101, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:07:47 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.